478 related articles for article (PubMed ID: 30902669)
1. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.
Di Forti M; Quattrone D; Freeman TP; Tripoli G; Gayer-Anderson C; Quigley H; Rodriguez V; Jongsma HE; Ferraro L; La Cascia C; La Barbera D; Tarricone I; Berardi D; Szöke A; Arango C; Tortelli A; Velthorst E; Bernardo M; Del-Ben CM; Menezes PR; Selten JP; Jones PB; Kirkbride JB; Rutten BP; de Haan L; Sham PC; van Os J; Lewis CM; Lynskey M; Morgan C; Murray RM;
Lancet Psychiatry; 2019 May; 6(5):427-436. PubMed ID: 30902669
[TBL] [Abstract][Full Text] [Related]
2. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.
Di Forti M; Marconi A; Carra E; Fraietta S; Trotta A; Bonomo M; Bianconi F; Gardner-Sood P; O'Connor J; Russo M; Stilo SA; Marques TR; Mondelli V; Dazzan P; Pariante C; David AS; Gaughran F; Atakan Z; Iyegbe C; Powell J; Morgan C; Lynskey M; Murray RM
Lancet Psychiatry; 2015 Mar; 2(3):233-8. PubMed ID: 26359901
[TBL] [Abstract][Full Text] [Related]
3. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
Quattrone D; Ferraro L; Tripoli G; La Cascia C; Quigley H; Quattrone A; Jongsma HE; Del Peschio S; Gatto G; ; Gayer-Anderson C; Jones PB; Kirkbride JB; La Barbera D; Tarricone I; Berardi D; Tosato S; Lasalvia A; Szöke A; Arango C; Bernardo M; Bobes J; Del Ben CM; Menezes PR; Llorca PM; Santos JL; Sanjuán J; Tortelli A; Velthorst E; de Haan L; Rutten BPF; Lynskey MT; Freeman TP; Sham PC; Cardno AG; Vassos E; van Os J; Morgan C; Reininghaus U; Lewis CM; Murray RM; Di Forti M
Psychol Med; 2021 Jun; 51(8):1329-1337. PubMed ID: 32183927
[TBL] [Abstract][Full Text] [Related]
4. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study.
Rodríguez-Toscano E; Alloza C; Fraguas D; Durán-Cutilla M; Roldán L; Sánchez-Gutiérrez T; López-Montoya G; Parellada M; Moreno C; Gayer-Anderson C; Jongsma HE; Di Forti M; Quattrone D; Velthorst E; de Haan L; Selten JP; Szöke A; Llorca PM; Tortelli A; Bobes J; Bernardo M; Sanjuán J; Luis Santos J; Arrojo M; Tarricone I; Berardi D; Ruggeri M; Lasalvia A; Ferraro L; La Cascia C; La Barbera D; Menezes PR; Del-Ben CM; ; Rutten BP; van Os J; Jones PB; Murray RM; Kirkbride JB; Morgan C; Díaz-Caneja CM; Arango C
Schizophr Bull; 2023 Sep; 49(5):1269-1280. PubMed ID: 37467351
[TBL] [Abstract][Full Text] [Related]
5. Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients.
Katz G; Kunyvsky Y; Hornik-Lurie T; Raskin S; Abramowitz MZ
Isr J Psychiatry Relat Sci; 2016; 53(3):10-15. PubMed ID: 28492376
[TBL] [Abstract][Full Text] [Related]
6. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.
Schoeler T; Petros N; Di Forti M; Klamerus E; Foglia E; Ajnakina O; Gayer-Anderson C; Colizzi M; Quattrone D; Behlke I; Shetty S; McGuire P; David AS; Murray R; Bhattacharyya S
Lancet Psychiatry; 2016 Oct; 3(10):947-953. PubMed ID: 27567467
[TBL] [Abstract][Full Text] [Related]
7. Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study.
D'Andrea G; Quattrone D; Malone K; Tripoli G; Trotta G; Spinazzola E; Gayer-Anderson C; Jongsma HE; Sideli L; Stilo SA; La Cascia C; Ferraro L; Lasalvia A; Tosato S; Tortelli A; Velthorst E; de Haan L; Llorca PM; Rossi Menezes P; Santos JL; Arrojo M; Bobes J; Sanjuán J; Bernardo M; Arango C; Kirkbride JB; Jones PB; Rutten BP; Van Os J; Selten JP; Vassos E; Schürhoff F; Szöke A; Pignon B; O'Donovan M; Richards A; Morgan C; Di Forti M; Tarricone I; Murray RM
Psychol Med; 2024 Jun; 54(8):1810-1823. PubMed ID: 38288603
[TBL] [Abstract][Full Text] [Related]
8. High-potency cannabis and the risk of psychosis.
Di Forti M; Morgan C; Dazzan P; Pariante C; Mondelli V; Marques TR; Handley R; Luzi S; Russo M; Paparelli A; Butt A; Stilo SA; Wiffen B; Powell J; Murray RM
Br J Psychiatry; 2009 Dec; 195(6):488-91. PubMed ID: 19949195
[TBL] [Abstract][Full Text] [Related]
9. Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use.
Sideli L; Fisher HL; Murray RM; Sallis H; Russo M; Stilo SA; Paparelli A; Wiffen BDR; O'Connor JA; Pintore S; Ferraro L; La Cascia C; La Barbera D; Morgan C; Di Forti M
Early Interv Psychiatry; 2018 Apr; 12(2):135-142. PubMed ID: 26560802
[TBL] [Abstract][Full Text] [Related]
10. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.
Schoeler T; Petros N; Di Forti M; Klamerus E; Foglia E; Murray R; Bhattacharyya S
Lancet Psychiatry; 2017 Aug; 4(8):627-633. PubMed ID: 28705600
[TBL] [Abstract][Full Text] [Related]
11. The contribution of cannabis use to the increased psychosis risk among minority ethnic groups in Europe.
Selten JP; Di Forti M; Quattrone D; Jones PB; Jongsma HE; Gayer-Anderson C; Szöke A; Llorca PM; Arango C; Bernardo M; Sanjuan J; Santos JL; Arrojo M; Tarricone I; Berardi D; Lasalvia A; Tosato S; la Cascia C; Velthorst E; van der Ven EMA; de Haan L; Rutten BP; van Os J; Kirkbride JB; Morgan CM; Murray RM; Termorshuizen F
Psychol Med; 2024 May; ():1-10. PubMed ID: 38721761
[TBL] [Abstract][Full Text] [Related]
12. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.
Di Forti M; Iyegbe C; Sallis H; Kolliakou A; Falcone MA; Paparelli A; Sirianni M; La Cascia C; Stilo SA; Marques TR; Handley R; Mondelli V; Dazzan P; Pariante C; David AS; Morgan C; Powell J; Murray RM
Biol Psychiatry; 2012 Nov; 72(10):811-6. PubMed ID: 22831980
[TBL] [Abstract][Full Text] [Related]
13. A large-scale genome-wide association study meta-analysis of cannabis use disorder.
Johnson EC; Demontis D; Thorgeirsson TE; Walters RK; Polimanti R; Hatoum AS; Sanchez-Roige S; Paul SE; Wendt FR; Clarke TK; Lai D; Reginsson GW; Zhou H; He J; Baranger DAA; Gudbjartsson DF; Wedow R; Adkins DE; Adkins AE; Alexander J; Bacanu SA; Bigdeli TB; Boden J; Brown SA; Bucholz KK; Bybjerg-Grauholm J; Corley RP; Degenhardt L; Dick DM; Domingue BW; Fox L; Goate AM; Gordon SD; Hack LM; Hancock DB; Hartz SM; Hickie IB; Hougaard DM; Krauter K; Lind PA; McClintick JN; McQueen MB; Meyers JL; Montgomery GW; Mors O; Mortensen PB; Nordentoft M; Pearson JF; Peterson RE; Reynolds MD; Rice JP; Runarsdottir V; Saccone NL; Sherva R; Silberg JL; Tarter RE; Tyrfingsson T; Wall TL; Webb BT; Werge T; Wetherill L; Wright MJ; Zellers S; Adams MJ; Bierut LJ; Boardman JD; Copeland WE; Farrer LA; Foroud TM; Gillespie NA; Grucza RA; Harris KM; Heath AC; Hesselbrock V; Hewitt JK; Hopfer CJ; Horwood J; Iacono WG; Johnson EO; Kendler KS; Kennedy MA; Kranzler HR; Madden PAF; Maes HH; Maher BS; Martin NG; McGue M; McIntosh AM; Medland SE; Nelson EC; Porjesz B; Riley BP; Stallings MC; Vanyukov MM; Vrieze S; ; Davis LK; Bogdan R; Gelernter J; Edenberg HJ; Stefansson K; Børglum AD; Agrawal A
Lancet Psychiatry; 2020 Dec; 7(12):1032-1045. PubMed ID: 33096046
[TBL] [Abstract][Full Text] [Related]
14. The contribution of childhood maltreatment to the incidence of heavy cannabis use in Iran (IRNS-CCI): A multicenter, matched-pairs, nested, case-control study.
Pirnia B; Soleimani A; Farhoudian A; Zahiroddin A
Child Abuse Negl; 2024 Mar; 149():106632. PubMed ID: 38368781
[TBL] [Abstract][Full Text] [Related]
15. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation.
Stone JM; Fisher HL; Major B; Chisholm B; Woolley J; Lawrence J; Rahaman N; Joyce J; Hinton M; Johnson S; Young AH;
Psychol Med; 2014 Feb; 44(3):499-506. PubMed ID: 23701858
[TBL] [Abstract][Full Text] [Related]
16. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank.
Ronaldson A; Arias de la Torre J; Prina M; Armstrong D; Das-Munshi J; Hatch S; Stewart R; Hotopf M; Dregan A
Lancet Reg Health Eur; 2021 Sep; 8():100149. PubMed ID: 34557851
[TBL] [Abstract][Full Text] [Related]
17. Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.
Jongsma HE; Gayer-Anderson C; Tarricone I; Velthorst E; van der Ven E; Quattrone D; di Forti M; ; Menezes PR; Del-Ben CM; Arango C; Lasalvia A; Berardi D; La Cascia C; Bobes J; Bernardo M; Sanjuán J; Santos JL; Arrojo M; de Haan L; Tortelli A; Szöke A; Murray RM; Rutten BP; van Os J; Morgan C; Jones PB; Kirkbride JB
Psychol Med; 2021 Jul; 51(9):1536-1548. PubMed ID: 32122439
[TBL] [Abstract][Full Text] [Related]
18. Effect of high-potency cannabis on corpus callosum microstructure.
Rigucci S; Marques TR; Di Forti M; Taylor H; Dell'Acqua F; Mondelli V; Bonaccorso S; Simmons A; David AS; Girardi P; Pariante CM; Murray RM; Dazzan P
Psychol Med; 2016 Mar; 46(4):841-54. PubMed ID: 26610039
[TBL] [Abstract][Full Text] [Related]
19. Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis.
Malcolm CP; Picchioni MM; DiForti M; Sugranyes G; Cooke E; Joseph C; McQueen G; Paparelli A; Stilo S; O'Connor J; Morgan C; Murray RM; Hodgins S
Schizophr Res; 2011 Mar; 126(1-3):81-6. PubMed ID: 21186097
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
